CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / Lexicon Pharmaceuticals, INC. (LXRX) / sotagliflozin
Forward catalyst · LXRX

sotagliflozin

Sponsor Lexicon Pharmaceuticals, INC. · listed as LXRX

READOUT Phase 3 Confidence: medium Source: clinicaltrials

sotagliflozin is a clinical-stage drug asset sponsored by Lexicon Pharmaceuticals, INC., listed as LXRX. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Jul 2026 (month precision, medium confidence), tied to trial NCT06481891. The asset is in Phase 3 and currently recruiting, studied in Obstructive Cardiomyopathy, Hypertrophic. It appears across 2 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2026-07-31
As disclosedJul 2026
Date precisionmonth
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT06481891
PhasePHASE3
StatusRECRUITING
Lead sponsorLexicon Pharmaceuticals
Listed asLXRX
Condition(s)Obstructive Cardiomyopathy, Hypertrophic; Non-obstructive Hypertrophic Cardiomyopathy
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 →   More LXRX catalysts